Latest Biotech Sector News

Page 2 of 4
Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.
Ada Torres
Ada Torres
30 Sept 2025
Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.
Ada Torres
Ada Torres
30 Sept 2025
Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.
Ada Torres
Ada Torres
29 Sept 2025
Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.
Ada Torres
Ada Torres
23 Sept 2025
Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.
Ada Torres
Ada Torres
22 Sept 2025
PYC Therapeutics announces the resignation of CEO Dr Rohan Hockings, appointing Chairman Alan Tribe as interim Managing Director while searching for a permanent replacement.
Ada Torres
Ada Torres
17 Sept 2025
Spacetalk Ltd has raised $4.05 million through a combination of a conditional placement and convertible notes to accelerate its geographic expansion and app development, alongside appointing a seasoned director to its board.
Sophie Babbage
Sophie Babbage
15 Sept 2025
Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.
Ada Torres
Ada Torres
8 Sept 2025
Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.
Ada Torres
Ada Torres
29 Aug 2025
PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.
Ada Torres
Ada Torres
28 Aug 2025
Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.
Ada Torres
Ada Torres
28 Aug 2025
Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.
Ada Torres
Ada Torres
28 Aug 2025